Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?

Keeling, 2009, International diabetes federation – the global voice for diabetes, European Endocrinology, 5, 10.17925/EE.2009.05.00.18

Saeedi, 2020, Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: results from the international diabetes federation diabetes atlas, Diabetes Research and Clinical Practice, 162, 108086, 10.1016/j.diabres.2020.108086

DeFronzo, 1988, The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM, Diabetes, 37, 667, 10.2337/diab.37.6.667

Palmer, 2015, Cellular senescence in type 2 diabetes: a therapeutic opportunity, Diabetes, 64, 2289, 10.2337/db14-1820

Accili, 2016, When β-cells fail: lessons from dedifferentiation, Diabetes, Obesity and Metabolism, 18, 117, 10.1111/dom.12723

Defronzo, 2009, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 58, 773, 10.2337/db09-9028

Cernea, 2013, Diabetes and beta cell function: from mechanisms to evaluation and clinical implications, Biochemical Medicine, 23, 266, 10.11613/BM.2013.033

Pørksen, 2002, Pulsatile insulin secretion: detection, regulation, and role in diabetes, Diabetes, 51, S245, 10.2337/diabetes.51.2007.S245

Matveyenko, 2012, Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling, Diabetes, 61, 2269, 10.2337/db11-1462

DeFronzo, 2009, Skeletal muscle insulin resistance is the primary defect in type 2 diabetes, Diabetes Care, 32, S157, 10.2337/dc09-S302

Boersma, 2018, Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: a Combined PET/MR Study, Hormone and Metabolic Research, 50, 627, 10.1055/a-0643-4739

Duncan, 2007, Regulation of lipolysis in adipocytes, Annual Review of Nutrition, 27, 79, 10.1146/annurev.nutr.27.061406.093734

Petersen, 2017, Regulation of hepatic glucose metabolism in health and disease, Nature Reviews Endocrinology, 13, 572, 10.1038/nrendo.2017.80

Pellegrinelli, 2016, Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues, Diabetologia, 59, 1075, 10.1007/s00125-016-3933-4

Hue, 2009, The Randle cycle revisited: a new head for an old hat, American Journal of Physiology. Endocrinology and Metabolism, 297, E578, 10.1152/ajpendo.00093.2009

Ter Horst, 2017, Hepatic diacylglycerol-associated protein kinase cepsilon translocation links hepatic steatosis to hepatic insulin resistance in humans, Cell Reports, 19, 1997, 10.1016/j.celrep.2017.05.035

Birkenfeld, 2014, Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes, Hepatology, 59, 713, 10.1002/hep.26672

Sparks, 2009, FoxO1 and hepatic lipid metabolism, Current Opinion in Lipidology, 20, 10.1097/MOL.0b013e32832b3f4c

Brown, 2008, Selective versus total insulin resistance: a pathogenic paradox, Cell Metabolism, 7, 95, 10.1016/j.cmet.2007.12.009

Oh, 2018, Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes, Frontiers in Endocrinology, 9, 384, 10.3389/fendo.2018.00384

Ashcroft, 2017, Is type 2 diabetes a glycogen storage disease of pancreatic β cells?, Cell Metabolism, 26, 17, 10.1016/j.cmet.2017.05.014

Wijsman, 2011, Familial longevity is marked by enhanced insulin sensitivity, Aging Cell, 10, 114, 10.1111/j.1474-9726.2010.00650.x

Thompson, 2019, Targeted elimination of senescent beta cells prevents type 1 diabetes, Cell Metabolism, 29, 1045, 10.1016/j.cmet.2019.01.021

Merino, 2017, A decade of genetic and metabolomic contributions to type 2 diabetes risk prediction, Current Diabetes Reports, 17, 135, 10.1007/s11892-017-0958-0

1997, Report of the expert committee on the diagnosis and classification of diabetes mellitus, Diabetes Care, 20, 1183, 10.2337/diacare.20.7.1183

Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, The Lancet Diabetes & Endocrinology, 6, 361, 10.1016/S2213-8587(18)30051-2

Dennis, 2019, Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data, The Lancet Diabetes & Endocrinology, 7, 442, 10.1016/S2213-8587(19)30087-7

2020, 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2020, Diabetes Care, 43, S98, 10.2337/dc20-S009

Buse, 2019, Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD), Diabetes Care

Herman, 2005, The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance, Annals of Internal Medicine, 142, 323, 10.7326/0003-4819-142-5-200503010-00007

Brown, 2008, Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data, Pediatric Diabetes, 9, 14, 10.1111/j.1399-5448.2007.00272.x

Chen, 2008, Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy, Diabetes Care, 31, 1927, 10.2337/dc08-0075

Baik, 2020, Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus, BMJ Open Diabetes Research and Care, 8, 10.1136/bmjdrc-2019-000940

Abdul-Ghani, 2015, Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus, American Journal of Physiology - Renal Physiology, 309, F889, 10.1152/ajprenal.00267.2015

Chao, 2010, SGLT2 inhibition-a novel strategy for diabetes treatment, Nature Reviews Drug Discovery, 9, 551, 10.1038/nrd3180

Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, New England Journal of Medicine, 377, 644, 10.1056/NEJMoa1611925

Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, New England Journal of Medicine, 373, 2117, 10.1056/NEJMoa1504720

Kaneto, 2017, Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic beta-cell function and reduction of insulin resistance, Journal of Diabetes, 9, 219, 10.1111/1753-0407.12494

Merovci, 2016, Effect of dapagliflozin with and without acipimox on insulin sensitivity and insulin secretion in T2DM males, Journal of Clinical Endocrinology & Metabolism, 101, 1249, 10.1210/jc.2015-2597

Merovci, 2015, Dapagliflozin lowers plasma glucose concentration and improves beta-cell function, Journal of Clinical Endocrinology & Metabolism, 100, 1927, 10.1210/jc.2014-3472

Forst, 2018, Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: an Exploratory Mechanistic Study, Hormone and Metabolic Research, 50, 403, 10.1055/a-0591-9442

Forst, 2017, Effects on alpha- and beta-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: an exploratory mechanistic study, Diabetes, Obesity and Metabolism, 19, 489, 10.1111/dom.12838

Ferrannini, 2014, Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients, Journal of Clinical Investigation, 124, 499, 10.1172/JCI72227

Bode, 2015, Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes, Diabetes, Obesity and Metabolism, 17, 294, 10.1111/dom.12428

Del Prato, 2015, Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data, Diabetes, Obesity and Metabolism, 17, 581, 10.1111/dom.12459

Leiter, 2015, Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study, Diabetes Care, 38, 355, 10.2337/dc13-2762

Wilding, 2014, Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years, Diabetes, Obesity and Metabolism, 16, 124, 10.1111/dom.12187

Goodpaster, 1999, Effects of weight loss on regional fat distribution and insulin sensitivity in obesity, Diabetes, 48, 839, 10.2337/diabetes.48.4.839

Merovci, 2014, Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production, Journal of Clinical Investigation, 124, 509, 10.1172/JCI70704

Mudaliar, 2014, Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin, Diabetes Technology & Therapeutics, 16, 137, 10.1089/dia.2013.0167

Daniele, 2016, Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes, Diabetes Care, 39, 2036, 10.2337/dc15-2688

Matsuba, 2018, Tofogliflozin decreases body fat mass and improves peripheral insulin resistance, Diabetes, Obesity and Metabolism, 20, 1311, 10.1111/dom.13211

Latva-Rasku, 2019, The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients, Diabetes Care, 42, 931, 10.2337/dc18-1569

Martinez, 2018, Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy, Diabetes, 67, 1182, 10.2337/db17-1278

Alatrach, 2020, Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors, Diabetes, 69, 681, 10.2337/db19-0770

Solis-Herrera, 2020, Increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal denervation and correlates strongly with the increase in urinary glucose excretion, Diabetes Care, 43, 1065, 10.2337/dc19-2177

Ferrannini, 2016, Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes, Diabetes, 65, 1190, 10.2337/db15-1356

Eriksson, 2018, Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study, Diabetologia, 61, 1923, 10.1007/s00125-018-4675-2

Kahl, 2020, Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial, Diabetes Care, 43, 298, 10.2337/dc19-0641

Bolinder, 2012, Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin, Journal of Clinical Endocrinology & Metabolism, 97, 1020, 10.1210/jc.2011-2260

Ferrannini, 2015, Energy balance after sodium–glucose cotransporter 2 inhibition, Diabetes Care, 38, 1730, 10.2337/dc15-0355

Tahara, 2018, Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats, Biomedicine & Pharmacotherapy, 105, 1033, 10.1016/j.biopha.2018.06.062

Zelniker, 2019, Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus, Circulation, 139, 2022, 10.1161/CIRCULATIONAHA.118.038868

Vilsbøll, 2009, The effects of glucagon-like peptide-1 on the beta cell, Diabetes, Obesity and Metabolism, 11, 11, 10.1111/j.1463-1326.2009.01073.x

Retnakaran, 2014, Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial, Diabetes Care, 37, 3270, 10.2337/dc14-0893

van Raalte, 2016, Exenatide improves beta-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial, European Journal of Endocrinology, 175, 345, 10.1530/EJE-16-0286

Anholm, 2017, Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes, Diabetes, Obesity and Metabolism, 19, 850, 10.1111/dom.12891

Santilli, 2017, Effects of liraglutide on weight loss, fat distribution, and β-cell function in obese subjects with prediabetes or early type 2 diabetes, Diabetes Care, 40, 1556, 10.2337/dc17-0589

Xu, 1999, Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats, Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270

Gastaldelli, 2016, Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study, Hepatology, 64, 2028, 10.1002/hep.28827

Zander, 2002, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study, Lancet, 359, 824, 10.1016/S0140-6736(02)07952-7

Anholm, 2019, Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease, Diabetology & Metabolic Syndrome, 11, 42, 10.1186/s13098-019-0438-6

Matsuda, 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp, Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462

Dutour, 2016, Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy, Diabetes, Obesity and Metabolism, 18, 882, 10.1111/dom.12680

Vilsbøll, 2012, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, BMJ, 344, 10.1136/bmj.d7771

Davies, 2015, Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial, JAMA, 314, 687, 10.1001/jama.2015.9676

Morales, 2011, The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors, Postgraduate Medicine, 123, 189, 10.3810/pgm.2011.11.2508

Thornberry, 2009, Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4), Best Practice & Research Clinical Endocrinology & Metabolism, 23, 479, 10.1016/j.beem.2009.03.004

Lyu, 2017, Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials, Scientific Reports, 7, 44865, 10.1038/srep44865

Derosa, 2013, Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin, Internal Medicine, 52, 2179, 10.2169/internalmedicine.52.8175

Aulinger, 2014, Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade, Diabetes, 63, 1079, 10.2337/db13-1455

Yanagimachi, 2016, Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects, Molecular Metabolism, 6, 226, 10.1016/j.molmet.2016.12.009

Pospisilik, 2002, Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats, Diabetes, 51, 943, 10.2337/diabetes.51.4.943

Derosa, 2014, Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation, Fundamental & clinical Pharmacology, 28, 221, 10.1111/fcp.12001

Foley, 2010, Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience, Vascular Health and Risk Management, 6, 541, 10.2147/VHRM.S10952

McKillop, 2018, Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion, Peptides, 100, 165, 10.1016/j.peptides.2017.12.020

Deacon, 2019, Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes, Frontiers in Endocrinology, 10, 80, 10.3389/fendo.2019.00080

Klein, 2014, Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis, Medical Molecular Morphology, 47, 137, 10.1007/s00795-013-0053-9

Ohyama, 2014, MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice, World Journal of Gastroenterology, 20, 16227, 10.3748/wjg.v20.i43.16227

Kawakubo, 2020, Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects, Scientific Reports, 10, 983, 10.1038/s41598-020-57935-6

Joy, 2017, Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial, World Journal of Gastroenterology, 23, 141, 10.3748/wjg.v23.i1.141

Kahn, 2000, Unraveling the mechanism of action of thiazolidinediones, Journal of Clinical Investigation, 106, 1305, 10.1172/JCI11705

Hauner, 2002, The mode of action of thiazolidinediones, Diabetes Metabolism Research Reviews, 18, S10, 10.1002/dmrr.249

Vidal-Puig, 1997, Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids, Journal of Clinical Investigation, 99, 2416, 10.1172/JCI119424

Davidson, 2018, Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future, Critical Reviews in Toxicology, 48, 52, 10.1080/10408444.2017.1351420

Zhang, 2002, PPAR and immune system-what do we know?, International Immunopharmacology, 2, 1029, 10.1016/S1567-5769(02)00057-7

Filipova, 2017, Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis, Diabetology & Metabolic Syndrome, 9, 90, 10.1186/s13098-017-0290-5

Lu, 2013, Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis, PloS One, 8, 10.1371/journal.pone.0076713

Gastaldelli, 2007, Thiazolidinediones improve beta-cell function in type 2 diabetic patients, American Journal of Physiology. Endocrinology and Metabolism, 292, E871, 10.1152/ajpendo.00551.2006

Scheen, 2009, Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18), Diabetic Medicine, 26, 1242, 10.1111/j.1464-5491.2009.02857.x

Gastaldelli, 2009, Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients, American Journal of Physiology. Endocrinology and Metabolism, 297, E225, 10.1152/ajpendo.90960.2008

Kawamori, 1998, Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group, Diabetes Research and Clinical Practice, 41, 35, 10.1016/S0168-8227(98)00056-4

Miyazaki, 2002, Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients, Journal of Clinical Endocrinology & Metabolism, 87, 2784, 10.1210/jcem.87.6.8567

Rasouli, 2005, Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue, American Journal of Physiology. Endocrinology and Metabolism, 288, E930, 10.1152/ajpendo.00522.2004

Wallace, 2004, An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study, Diabetic Medicine : A Journal of the British Diabetic Association, 21, 568, 10.1111/j.1464-5491.2004.01218.x

Yamasaki, 1997, Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 glucose clamp study group, Japan, Tohoku Journal of Experimental Medicine, 183, 173, 10.1620/tjem.183.173

Miyazaki, 2004, Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients, Journal of Clinical Endocrinology & Metabolism, 89, 4312, 10.1210/jc.2004-0190

Miyazaki, 2002, Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes, Diabetes Care, 25, 517, 10.2337/diacare.25.3.517

Cusi, 2016, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Annals of Internal Medicine, 165, 305, 10.7326/M15-1774

Miyazaki, 2001, Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone, Diabetes Care, 24, 710, 10.2337/diacare.24.4.710

Phielix, 2013, Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes, Diabetes, Obesity and Metabolism, 15, 915, 10.1111/dom.12112

Chiquette, 2004, A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors, Archives of Internal Medicine, 164, 2097, 10.1001/archinte.164.19.2097

Roden, 2009, Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes, Journal of Internal Medicine, 265, 476, 10.1111/j.1365-2796.2008.02040.x

Promrat, 2004, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis, Hepatology, 39, 188, 10.1002/hep.20012

Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, New England Journal of Medicine, 355, 2297, 10.1056/NEJMoa060326

Ravikumar, 2008, Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content, Diabetes, 57, 2288, 10.2337/db07-1828

Sathyanarayana, 2011, Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes, Obesity, 19, 2310, 10.1038/oby.2011.152

Zib, 2007, Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes, Journal of Investigative Medicine, 55, 230, 10.2310/6650.2007.00003

Martin, 2010, Effect of pioglitazone on energy intake and ghrelin in diabetic patients, Diabetes Care, 33, 742, 10.2337/dc09-1600

van der Meer, 2009, Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus, Circulation, 119, 2069, 10.1161/CIRCULATIONAHA.108.803916

Tripathy, 2016, Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: results from ACT NOW, Journal of Clinical Endocrinology & Metabolism, 101, 2056, 10.1210/jc.2015-4202

Erdmann, 2007, Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease, Diabetes Care, 30, 2773, 10.2337/dc07-0717